Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + QL1706 in HER2-expressing recurrent cervical cancer
NCT07172217Phase 2Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Oct 2025
- Primary completion
- Feb 2027
- Modality
- Immune Checkpoint Inhibitors, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin, iparomlimab and tuvonralimab in Cervical Cancer (CC), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Objective Response Rate at 6 months. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
disitamab vedotiniparomlimabtuvonralimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT07172217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07172217.